

Trial Nickname: START

Full Name: Strategic Timing of Antiretroviral Treatment

Participant Overview: A study for individuals with HIV who have not taken antiretroviral medications that will look at when to start treatment.

Major Eligibility Criteria:

- **CD4 count:** >500 cells/mm³
- **Viral load:** Any
- Antiretroviral-naïve

Description: This is a large, multicenter trial for participants who have CD4 counts >500 and are antiretroviral-naïve who are randomized to either begin HAART immediately or deferred until either their CD4 <350 or they develop symptoms. Both HIV and non-HIV endpoints will be observed. The pilot phase will enroll 900 participants and the definitive study will enroll at least 4000 subjects. The follow up will be between five and six years.

For more information, please contact:

Boston: Julia Green at 617.502.1711 or jgreen@crine.org